Kingswood Capital Partners Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$45 Price Target
1. Kingswood Capital Partners initiated coverage on QNTM with a BUY rating. 2. A US$45 price target is set based on successful drug trials. 3. Lucid-MS targets neurodegenerative and metabolic disorders, pivotal for QNTM's future. 4. Quantum retains significant ownership stake in Unbuzzd Wellness Inc. 5. Royalty payments from Unbuzzd could enhance QNTM's revenue stream.